Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study. Journal Abstract

Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.

Publication Date: 2024 Jun

Full Text Sources

Authors

Vicky Makker; Jose Alejandro Perez-Fidalgo; Giorgio Valabrega; Erika Hamilton; Toon Van Gorp; Jalid Sehouli; Klaudia Regináčová; Debra L Richardson; Tamar Perri; Amit M Oza; David S Miller; Eva Maria Guerra Alía; Ugo De Giorgi; Stephanie Henry; Daniel L Spitz; Pauline Wimberger; Markéta Bednaříková; Hye Sook Chon; Jerónimo Martínez-Garcia; Carmela Pisano; Jonathan S Berek; Ignacio Romero; Giovanni Scambia; Lorena Fariñas-Madrid; Joseph Buscema; Fabienne Schochter; Kai Li; Pratheek Kalyanapu; Christopher J Walker; Ignace Vergote

Abstract

OBJECTIVE

To report long-term efficacy and safety of selinexor maintenance therapy in adults with TP53 wild-type (TP53wt) stage IV or recurrent endometrial cancer (EC) who achieved partial remission (PR) or complete remission (CR) following chemotherapy.

Source

Gynecologic oncology

Pub Types(s)

Journal Article

Language

English

PubMed ID

38834399